<DOC>
	<DOCNO>NCT00669578</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , CC-4047 , may stimulate immune system different way stop cancer cell grow . CC-4047 may also stop growth cancer cell block blood flow cancer . PURPOSE : This trial study side effect best dose CC-4047 see well work treat patient myelofibrosis .</brief_summary>
	<brief_title>CC-4047 Treating Patients With Myelofibrosis</brief_title>
	<detailed_description>OBJECTIVES : Phase I : Primary - To determine Maximum Tolerated Dose CC-4047 treatment Primary , Post Polycythemia Vera , Post Essential Thrombocythemia Myelofibrosis ( PMF , post-PV MF , post-ET MF ) . Phase II : Primary - Best overall response determine International Working Group Criteria first 6 cycle ( 168 day ) study treatment . Secondary - Safety ( type , frequency , severity [ National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 3.0 ] adverse event ( AEs ) , relationship AEs CC-4047 . - Duration response . - Time response . - Best overall response determine International Working Group Criteria first 12 cycle ( 336 day ) study treatment . OUTLINE : Patients receive oral CC-4047 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 28 day every 6 month 3 year .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary post essential thrombocythemia ( ET ) post polycythemia vera ( PV ) myelofibrosis require therapy De novo presentation ( i.e. , agnogenic myeloid metaplasia AND post ET post PV myelofibrosis ) Developed antecedent history PV ( i.e. , post polycythemic myeloid metaplasia ) essential polycythemia ( i.e. , post thrombocythemic myeloid metaplasia ) Total hemoglobin &lt; 10 g/dL OR transfusion dependent anemia ( defined history ≥ 2 unit red blood cell ( RBC ) transfusion within past 28 day hemoglobin &lt; 8.5 g/dL associate overt bleed ) OR mark splenomegaly ( e.g. , ≥ 10 cm costal margin ) PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Absolute neutrophil count ( ANC ) ≥ 500/μL Platelet count ≥ 20,000/μL Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 3 time upper limit normal ( ULN ) ( ≤ 5 time ULN attribute hepatic extramedullary hematopoiesis ) Total bilirubin ≤ 3 time ULN OR direct bilirubin ≤ 2 time ULN Serum creatinine ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception ≥ 28 day , , ≥ 28 day completion study treatment Agrees abstain donate blood , semen , sperm ≥ 28 day completion study treatment Willing undergo transfusion blood product ( applicable ) Able complete questionnaire ( ) alone assistance No known HIV positivity , hepatitis B carrier , active hepatitis C infection No serious medical condition , psychiatric illness , condition , include presence laboratory abnormality , ( judge treat physician ) would preclude give informed consent participate study confound ability interpret data study No active malignancy , except basal cell squamous cell carcinoma skin carcinoma situ cervix breast No active deep vein thrombosis pulmonary embolism therapeutically anticoagulated PRIOR CONCURRENT THERAPY : Recovered prior therapy No prior CC4047 More 28 day since prior growth factor , cytotoxic chemotherapeutic agent ( e.g. , hydroxyurea anagrelide ) , corticosteroid , experimental drug therapies No concurrent experimental drug therapy cytotoxic chemotherapeutic agent ( e.g. , hydroxyurea anagrelide ) myelofibrosis No concurrent growth factor ( include erythropoietin ) myelofibrosis , except GCSF pegfilgrastim No concurrent chronic use ( i.e. , &gt; 2 week ) physiologic dos corticosteroid ( dose equivalent &gt; 10 mg/day prednisone )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>secondary myelofibrosis</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>primary myelofibrosis</keyword>
</DOC>